VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Comparison

Bacille Calmette-Guérin (BCG) Mycobacterium tuberculosis sigE mutant vaccine TICE BCG
Vaccine Information Vaccine Information Vaccine Information
  • Tradename: BCG
  • Vaccine Ontology ID: VO_0000771
  • CDC CVX code: 19
  • Type: Attenuated live vaccine
  • Preparation: The evaluation of BCG lacks comparability among the vaccination studies due to the use of six different BCG sub-strains [Copenhagen-1331, Pasteur-1173P, Glaxo-1077, Tokyo-172, Russian, Moreau]. The comparative genomic analysis of different BCG strains has shown that there is no uniformity among all presently used vaccines and this genetic variability may contribute to the variation in protective efficacy seen in different geographic regions of the world (Gupta et al., 2007).

    In one case, Calmette et al. (1923) used decreasing doses (1 mg, .01 mg, and .002 mg) of tubercle bacilli to infect guinea pigs s.c. Bacterial loads increased in response to decreasing dose sizes. Similar results were acquired for later intramuscular and intracerebral infection procedures by other groups (SWEDBERG, 1951)
  • Virulence: The original BCG strain lost its virulence after 39 passages by Albert Calmette and Camille Guerin, and was administered to humans i.d. on the 231st passage. The BCG bacteria showed altered colony morphologies and no virulence in experimental animals. BCG has shown a high degree of safety over the years (Ducati et al., 2006).

    --Calmette et al. used length of survival as a metric for virulence in their 1923 study (Agger et al., 2002).
    --The increased ability for M. bovis strains to retain virulence was noted by Lange in 1922 (SWEDBERG, 1951).
  • Description: Albert Calmette and Camille Guerin, two French scientists, made an attenuated strain from another mycobacterium (M. bovis) by growing it for 13 years on culture. They observed a reduction in the virulence in animals through this period. When infants were given this vaccine, it provided a reduction in mortality by 90%. Since then, Bacille Calmette Guerin [BCG] has become the most widely used vaccine throughout the world. It is estimated that more than 3 billion people have received BCG. The protective efficacy of BCG vaccine against adult pulmonary TB has varied dramatically from 80 to 0% (Gupta et al., 2007).

    Development of the BCG strain was predated by numerous M. tuberculosis studies from the 1890s-1920s, including (Lote 1889, Strauss 1895, Moriya 1909, Romer 1903, Weber 1912, Binder 1915, and Browning and Gulbransen 1926) in a diverse set of hosts (including mouse, avian, human, bovine, and guinea pig hosts) (SWEDBERG, 1951).

    Several new subunit booster vaccinations are under development, including Ag85, Mtb72F, HspX and other DosR-controlled gene products, Rv3407 and other Rpf-controlled gene products, and heparin-binding hemagglutinin (HBHA) (Kaufmann, 2005).
  • Vaccine Ontology ID: VO_0002795
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • sigE gene engineering:
    • Type: Gene mutation
    • Description: This sigE mutant is from Mycobacterium tuberculosis (Hernandez et al., 2010).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intratracheal immunization
  • Product Name: BCG Live
  • Tradename: TICE BCG
  • Manufacturer: Organon Teknika Corp
  • Vaccine Ontology ID: VO_0000103
  • CDC CVX code: 19
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA (License #0956)
  • Host Species for Licensed Use: Human
  • ag85A gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Preservative: No preservative in TICE BCG.
  • Preparation: TICE BCG is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. The TICE® strain was developed at the University of Illinois from a strain originated at the Pasteur Institute. The medium in which the BCG organism is grown for preparation of the freeze-dried cake is composed of the following ingredients: glycerin, asparagine, citric acid, potassium phosphate, magnesium sulfate, and iron ammonium citrate. The final preparation prior to freeze drying also contains lactose. The freeze-dried BCG preparation is delivered in glass vials, each containing 1 to 8 x 10^8 colony forming units (CFU) of TICE® BCG which is equivalent to approximately 50 mg wet weight. Determination of in-vitro potency is achieved through colony counts derived from a serial dilution assay. A single dose consists of 1 reconstituted vial.
  • Immunization Route: intravesicular infusion
  • Storage: This vaccine should be kept refrigerated.
  • Description: TICE® BCG induces a granulomatous reaction at the local site of administration. Intravesical TICE® BCG has been used as a therapy for, and prophylaxis against, recurrent tumors in patients with carcinoma in situ (CIS) of the urinary bladder, and to prevent recurrence of Stage TaT1 papillary tumors of the bladder at high risk of recurrence. It works against cancer as a biologic response modifier. Specifically, TICE BCG has no direct antitumor effect but is able to stimulate inflammatory immune response in the bladder wall that, in turn, destroys cancer cells within the bladder. TICE BCG vaccination may cause a false-positive reaction to the TST (Tuberculin Skin Test), which may complicate decisions about prescribing treatment.
Host Response Host Response Host Response

Human Response

  • Immune Response: TB Ag-specific mucosal, humoral and cellular immune response via T cell proliferation and production (Wang et al., 2009).
  • Description: SL(E6-85B) vaccine, when combined with BCG vaccination, induced the strongest TB Ag-specific mucosal, humoral, and cellular immune responses comprised of increased proliferation of T cells, IFN-gamma expression, granzyme B production (Wang et al., 2009).
  • Host Ifng (Interferon gamma) response
    • Description: The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced significant TB Ag-specific IFN-gamma immune responses in splenocytes. Splenocytes were stimulated with the Ag85B protein 2 weeks after the final immunization (Wang et al., 2009).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: DNA was obtained from the peripheral blood of 99 NMIBC patients who were prospectively randomized to receive postresection intravesical BCG or BCG with interferon alpha. (Chiong et al., 2011)
  • Immune Response: Patients with the NRAMP1 D543N G:G genotype and allele 3 (GT)n polymorphism had decreased recurrence time after BCG therapy. (Chiong et al., 2011)
  • Host GPX1 response
    • Description: Polymorphisms of the GPX1 gene may be associated with recurrence of BCa after BCG immunotherapy. (Chiong et al., 2011)
    • Detailed Gene Information: Click Here.
  • Host SLC11A1 response
    • Description: Polymorphisms of the SLC11A1 genes may be associated with recurrence of BCa after BCG immunotherapy. (Chiong et al., 2011)
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: Intradermally vaccinated the infants within 48 hours of birth. Examination of whole blood stimulated ex vivo with 1.2×106 CFU BCG 10 weeks after newborn BCG vaccination of South African infants (Randhawa et al., 2011).
  • Immune Response: Increased production of TH1-type T cell cytokines (Randhawa et al., 2011).
  • Host GPX1 response
    • Description: After stimulation with TLR6 lipopeptide ligands, PBMCs from TLR6-deficient, BCG-vaccinated individuals secreted lower amounts of IL-6 and IL-10 compared to those with responsive TLR6 genotypes (Randhawa et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host human IFNG response
    • Description: Increased IFNG production associated with TLR1/6 presence 10 weeks post BCG vaccination (Randhawa et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL10 response
    • Description: IL10 expression post vaccination increased in presence of TLR1/6 (Randhawa et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL2 response
    • Description: Increased IL2 production associated with TLR1/6 presence 10 weeks post BCG vaccination (Randhawa et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL6 response
    • Description: IL6 expression post vaccination expressed in higher amounts in presence of TLR1/6 (Randhawa et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TLR1 response
    • Description: After stimulation with TLR1 lipopeptide ligands, PBMCs from TLR1-deficient, BCG-vaccinated individuals secreted lower amounts of IL-6 and IL-10 compared to those with responsive TLR1 genotypes (Randhawa et al., 2011).
    • Detailed Gene Information: Click Here.

Human Response

  • Description: The human monocytic cell line THP-1 was obtained from the ATCC, and cultures were grown (Fontán et al., 2008).
  • Host APOBEC3B response
    • Description: A sigE mutant upregulates APOBEC3B in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host C19orf66 response
    • Description: A sigE mutant upregulates C19orf66 in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host CD70 response
    • Description: A sigE mutant upregulates CD70 in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host GPR182 response
    • Description: A sigE mutant upregulates GPR182 in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host HIST1H2BE response
    • Description: A sigE mutant upregulates HIST1H2BE in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host HIST2H4A response
    • Description: A sigE mutant upregulates HIST2H4A in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host PCDHB1 response
    • Description: A sigE mutant upregulates PCDHB1 in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host PTCD1 response
    • Description: A sigE mutant upregulates PTCD1 in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host STAG3 response
    • Description: A sigE mutant upregulates STAG3 in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host TBX21 response
    • Description: A sigE mutant upregulates TBX21 in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host TSC22D4 response
    • Description: A sigE mutant upregulates TSC22D4 in human THP-1 cells, which was not significantly upregulated after infection with the wild type pathogen (Fontán et al., 2008).
    • Detailed Gene Information: Click Here.

Human Response

  • Vaccination Protocol: A large scale trial evaluating the efficacy of BCG was conducted from 1956 to 1963 and involved almost 60,000 school children who received BCG at the age of 14 or 15 (FDA: TICE BCG).
  • Side Effects: Side effects of vaccination include: headache, fever, hardening of skin at injection site, and swelling of the lymph nodes near the injection site. The most common side effect is large scars that remain on the skin at the injection site (FDA: TICE BCG).
  • Efficacy: The efficacy of this vaccine has been shown to vary between clinical studies. For example, in this study, the efficacy was found to be 84% up to 6 years after immunization but in another study, a US Public Health Service trial, of BCG in Georgia and Alabama published in 1966 showed an efficacy of only 14% (FDA: TICE BCG).

Mouse Response

  • Host Ifng (Interferon gamma) response
    • Description: Immunization with BCG[pMV361] (BCG with empty pMV361) vaccine induced significant up regulation of IFN-gamma in mice 45 days after immunization as compared to non-immunized mice. Cytokines were measured in lymphocytes from the spleen (Singh et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host IL-6 response
    • Description: Immunization with BCG[pMV361] (BCG with empty pMV361) vaccine induced significant up regulation of IL-6 in mice 45 days after immunization as compared to non-immunized mice. Cytokines were measured in lymphocytes from the spleen (Singh et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host Il2 response
    • Description: Immunization with BCG[pMV361] (BCG with empty pMV361) vaccine induced significant up regulation of IL-2 in mice 45 days after immunization as compared to non-immunized mice. Cytokines were measured in lymphocytes from the spleen (Singh et al., 2011).
    • Detailed Gene Information: Click Here.
  • Host TNF-alpha response
    • Description: Immunization with BCG[pMV361] (BCG with empty pMV361) vaccine induced significant up regulation of TNF-alpha in mice 45 days after immunization as compared to non-immunized mice. Cytokines were measured in lymphocytes from the spleen (Singh et al., 2011).
    • Detailed Gene Information: Click Here.

Mouse Response

  • Host Strain: C57BL/6
  • Vaccination Protocol: Ten to twelve female C57BL/6 mice were immunized per group with 100 μl of the formulation, once, subcutaneously (s.c.) at the base of the tail. BCG and Lactoferrin were emulsified with Freund's adjuvant in a 1:1 ratio (Hwang et al., 2005).
  • Immune Response: A single immunization of mice with Lactoferrin as an adjunct adjuvant resulted in amplified splenocyte proliferative response to heat-killed BCG, and elevated IL-12(p40) production with increased relative ratios of IL-12/IL-10. Furthermore, splenocyte recall response to HK-BCG was augmented for proinflammatory mediators, TNF-alpha, IL-1beta, and IL-6, approaching responses generated to complete Freund's adjuvant (CFA) immunized controls (Hwang et al., 2005).
  • Challenge Protocol: Fourteen days post-immunization, four mice from each group were aerosol challenged with Erdman MTB (Hwang et al., 2005).
  • Efficacy: All immunization groups showed significant reduction in lung organism load, decreased bacterial load in the spleen (Hwang et al., 2005).
  • Host Ifng (Interferon gamma) response
    • Description: Lactoferrin was able to significantly augment the production of IFN-γ compared to vaccine preparations in IFA alone (Hwang et al., 2005).
    • Detailed Gene Information: Click Here.
  • Host IL-1b response
    • Description: In concert with the increased stimulation index, there was significant production of all three proinflammatory mediators (TNF-alpha, IL-1beta, and IL-6) in the Lactoferrin immunization group compared to both the non-immunized and IFA immunized groups (Hwang et al., 2005).
    • Detailed Gene Information: Click Here.
  • Host IL-6 response
    • Description: In concert with the increased stimulation index, there was significant production of all three proinflammatory mediators (TNF-alpha, IL-1beta, and IL-6) in the Lactoferrin immunization group compared to both the non-immunized and IFA immunized groups (Hwang et al., 2005).
    • Detailed Gene Information: Click Here.
  • Host Il12b response
    • Description: A single administration of BCG in IFA and Lactoferrin resulted in significantly increased production of IL-12 in the splenic recall assay (Hwang et al., 2005).
    • Detailed Gene Information: Click Here.
  • Host Ltf response
    • Description: Lactoferrin can act as an adjunct adjuvant to augment cellular immunity and boost BCG efficacy for protection against subsequent challenge with virulent MTB. Augmented responses were found for IL-12, TNF-alpha, IL-1beta, and IL-6 (Hwang et al., 2005).
    • Detailed Gene Information: Click Here.
  • Host TNF-alpha response
    • Description: In concert with the increased stimulation index, there was significant production of all three proinflammatory mediators (TNF-alpha, IL-1beta, and IL-6) in the Lactoferrin immunization group compared to both the non-immunized and IFA immunized groups (Hwang et al., 2005).
    • Detailed Gene Information: Click Here.

Mouse Response

  • Persistence: A sigE mutant is attenuated in mice (Hernandez et al., 2010).
  • Efficacy: A sigE mutant induces significant protection in mice from challenge with wild type M. tuberculosis (Hernandez et al., 2010).
  • Host Defb3 response
    • Description: A sigE mutant showed a significantly higher and constant expression of the gene encoding β-defensin 3 in the lungs beginning the 7th day post vaccination until the 28th day as compared to mice infected with the parental strain (Hernandez et al., 2010).
    • Detailed Gene Information: Click Here.
  • Host Ifng (Interferon gamma) response
    • Description: A sigE mutant showed a significantly higher and constant expression of the gene encoding IFN-γ as compared to mice infected with the parental strain. IFN-gamma was significantly upregulated in mice lungs after vaccination with the mutant as compared to infection with the wild type beginning day 1 post-infection and continuing throughout the duration of the experiment (Hernandez et al., 2010).
    • Detailed Gene Information: Click Here.
  • Host Il10 (interleukin 10) response
    • Description: The expression of IL-10 was higher in sigE mutant-infected mice lungs as compared to infection with the parental strain, but it was significant only 21 and 28 days after the infection (Hernandez et al., 2010).
    • Detailed Gene Information: Click Here.
  • Host Il4 (interleukin 4) response
    • Description: IL-4 was expressed at a significantly lower level in the sigE mutant-infected mice as compared to mice infected with the wild type pathogen. Significant down regulation of IL-4 by the mutant in mouse lungs was seen days 1-28 post infection as compared to infection with the wild type (Hernandez et al., 2010).
    • Detailed Gene Information: Click Here.
  • Host TNF-alpha response
    • Description: A sigE mutant showed a significantly higher and constant expression of the gene encoding TNF-alpha as compared to mice infected with the parental strain. Vaccination with the mutant significantly up-regulated TNF-alpha in mice lungs on days 1, 21, and 28 post-infection as compared to infection with the wild type (Hernandez et al., 2010).
    • Detailed Gene Information: Click Here.

Rat Response

  • Host Strain: Wistar rat
  • Vaccination Protocol: Wistar rats were vaccinated with 10^6 BCG subcutaneously 6-8 weeks prior to challenge (Singhal et al., 2011).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: A significantly greater number of total cells and CD8 T cells was observed in BCG vaccinated animals at day 60 post-challenge compared with unvaccinated animals. Immunohistochemistry revealed substantial higher number of CB8 cells in the lung lesions of vaccinated rats at day 30. Finally, a high number of mycobacteria-specific CD4 and CD8 T cells producing IFN-gamma was detected in BCG vaccinated rats (Singhal et al., 2011).
  • Challenge Protocol: The rats were challenged with a low dose of Mtb W4 strain 6 weeks after vaccination (Singhal et al., 2011).
  • Efficacy: A significantly reduced bacillary load was observed in the lungs of BCG vaccinated rats over the entire course of infection. About a 1 log(10) reduced bacillary load was observed in the lungs of vaccinated rats compared to unvaccinated animals (Singhal et al., 2011).
  • Description: The study showed that BCG vaccinated Wistar rats efficiently control early bacillary growth and pathology related to Mtb infection (Singhal et al., 2011).

Rabbit Response

  • Host Strain: New Zealand White Rabbits
  • Vaccination Protocol: Rabbits were vaccinated three times at 3-week intervals intramuscularly with a total of 500 micro liters of BCG (Tsenova et al., 2006).
  • Persistence: Rabbits were euthanized 8 weeks post-infection (Tsenova et al., 2006).
  • Vaccine Immune Response Type: VO_0000134
  • Immune Response: Significantly smaller amounts of CFU of the bacterium were observed in the brains of rabbits that were vaccinated with BCG. No granulomas were found in the lungs of mice vaccinated with BCG while they were found in the unvaccinated group. Vaccination with BCG induced a statistically significant increase in antigen-specific T-cell proliferation compared to that of non-vaccinated controls (Tsenova et al., 2006).
  • Challenge Protocol: Ten weeks after immunization with BCG the rabbits were anesthetized and immobilized and a spinal needle was used to withdraw .3 mL of cerebrospinal fluid and .2 mL of 5X10^5 CFU of M. tuberculosis was injected intracisternally (Tsenova et al., 2006).
  • Efficacy: This study showed that vaccination with BCG induced protection against M. tuberculosis because rabbits that were vaccinated showed increased T-cell proliferation and no granulomas in the lungs (Tsenova et al., 2006).

Guinea pig Response

  • Host Strain: Dunkin Hartley (Thom et al., 2012).
  • Vaccination Protocol: Pathogen-free, female outbred Dunkin Hartley strain guinea pigs (weighing 500–550 g) were vaccinated subcutaneously with 5 × 104 colony forming units (CFU) of M. bovis BCG Pasteur (Thom et al., 2012).
  • Immune Response: Significant down-regulation of both ferritin light- and heavy-chain (Thom et al., 2012).
  • Description: PPD from M. tuberculosis was added to splenocytes from BCG-vaccinated guinea pigs at a final concentration of 30 μg/ml for 16 and 24 h at 37 °C in the presence of 5% CO2. The splenocyte cultures from naïve and BCG-vaccinated guinea pigs were infected with M. tuberculosis at an MOI of 0.2 and incubated for 4, 16 and 24 h at 37 °C in the presence of 5% CO2. The viability of uninfected and infected splenocytes from the same vaccination group was determined at 4, 16 and 24 h post-M. tuberculosis infection by trypan blue exclusion (Thom et al., 2012).
  • Host Fth1 response
    • Description: Splenocytes from BCG-vaccinated guinea pigs were stimulated ex vivo with purified protein derivative from M. tuberculosis and a significant down-regulation of ferritin light- and heavy-chain was measured by reverse-transcription quantitative-PCR (Thom et al., 2012).
    • Detailed Gene Information: Click Here.
  • Host Ftl response
    • Description: Splenocytes from BCG-vaccinated guinea pigs were stimulated ex vivo with purified protein derivative from M. tuberculosis and a significant down-regulation of ferritin light- and heavy-chain was measured by reverse-transcription quantitative-PCR (Thom et al., 2012).
    • Detailed Gene Information: Click Here.

Cattle Response

  • Host Strain: Friesian Calves
  • Vaccination Protocol: Vaccinated subcutaneously in the neck with 2 mL of 2X10^5 cfu BCG
  • Persistence: Cattle were examined 154 to 164 days after they had been challenged.
  • Vaccine Immune Response Type: VO_0000408
  • Immune Response: The cattle that had been vaccinated with BCG showed significantly less numbers of lesions in the lungs and lymph nodes.
  • Challenge Protocol: 54 days after vaccination the calves were challenged intratracheally with 2X10^3 cfu M. bovis strain 83/6235.
  • Efficacy: Vaccination with BCG induced considerable protection against a challenge with M. bovis, there were significantly fewer animals with Tuberculosis lesions.
  • Description: This study showed that killed M. vaccae did not protect against challenge by M. bovis, however, the vaccination of cattle with BCG by the respiratory route protected them against the development of tuberculous lung lesions.
  • Host IFNG response
    • Description: In the vaccinated cattle group, increased IFN-gamma was released from the culture of peripheral blood lymphocytes from cattle after stimulation with bovine purified protein derivative (PPD) (Buddle et al., 1995).
    • Detailed Gene Information: Click Here.
  • Host IL10 response
    • Description: In the vaccinated cattle group, increased IL-2 was released from the culture of peripheral blood lymphocytes from cattle after stimulation with bovine purified protein derivative (PPD) (Buddle et al., 1995).
    • Detailed Gene Information: Click Here.

Macaque Response

  • Host Strain: cynomolgus monkey (M. fascicularis) and rhesus monkey (M. mulatta)
  • Vaccination Protocol: The macaques were vaccinated intradermally with 1–4 X 10^5 cfu bacillus Calmette–Guerin
  • Vaccine Immune Response Type: VO_0000859
  • Immune Response: Showed specific cell-mediated immune responses after bacillus Calmette–Guerin vaccination as observed by skin test, lymphoproliferation, and IFN-gamma production (Langermans et al., 2001).
  • Challenge Protocol: 17 weeks after vaccination the monkeys were challenged with 3,000 cfu M. tuberculosis by intratracheal installation of 3 ml of the bacterial suspension. Between 59 and 65 days after infection the animals were killed, and necropsies were undertaken for pathological examination (Langermans et al., 2001).
  • Description: This study showed that cynomolgus monkey (M. fascicularis) is a better model than rhesus monkey (M. mulatta) for M. tuberculosis vaccination and infection studies. From a challenge with 3,000 cfu M. tuberculosis, BCG vaccination protects cynomolgus monkeys with >2-log reduction of the bacterial load and diminished pathology, whereas only a minimal BCG vaccination effect was observed in rhesus monkeys. These two species represent the two extremes of BCG-induced protection that is found in humans (Langermans et al., 2001).

Zebrafish Response

  • Host Strain: Wildtype AB or adult rag hu1999 mutant fish
  • Vaccination Protocol: Fish were vaccinated with ~8X10^3 CFU BCG intraperitoneally or intramuscularly (Oksanen et al., 2013).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Fish were anesthetized and intraperitoneally injected 3-4 weeks after immunization with ~20-30 bacteria (Oksanen et al., 2013).
  • Efficacy: BCG was unable to prevent infection with mycobacteria, however, it improved fish survival lowering the mortality rate from 84.2% to 45.0% (Oksanen et al., 2013).
  • Description: BCG is unable to prevent infection in zebrafish, however, it is able to improve fish survival (Oksanen et al., 2013).
References References References
Agger et al., 2002: Agger EM, Andersen P. A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine. 2002 Nov 22; 21(1-2); 7-14. [PubMed: 12443657 ].
Buddle et al., 1995: Buddle BM, Keen D, Thomson A, Jowett G, McCarthy AR, Heslop J, De Lisle GW, Stanford JL, Aldwell FE. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Research in veterinary science. 1995; 59(1); 10-16. [PubMed: 8525078].
Chiong et al., 2011: Chiong E, Kesavan A, Mahendran R, Chan YH, Sng JH, Lim YK, Kamaraj R, Tan TM, Esuvaranathan K. NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer. European urology. 2011; 59(3); 430-437. [PubMed: 21163569].
Ducati et al., 2006: Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption-- a review on tuberculosis. Memorias do Instituto Oswaldo Cruz. 2006 Nov; 101(7); 697-714. [PubMed: 17160276].
Gupta et al., 2007: Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine. 2007 May 10; 25(19); 3742-51. [PubMed: 17321015].
Hwang et al., 2005: Hwang SA, Kruzel ML, Actor JK. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. International immunopharmacology. 2005; 5(3); 591-599. [PubMed: 15683854].
Kaufmann, 2005: Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends in immunology. 2005 Dec; 26(12); 660-7. [PubMed: 16246622 ].
Langermans et al., 2001: Langermans JA, Andersen P, van Soolingen D, Vervenne RA, Frost PA, van der Laan T, van Pinxteren LA, van den Hombergh J, Kroon S, Peekel I, Florquin S, Thomas AW. Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(20); 11497-11502. [PubMed: 11562492].
Oksanen et al., 2013: Oksanen KE, Halfpenny NJ, Sherwood E, Harjula SK, Hammarén MM, Ahava MJ, Pajula ET, Lahtinen MJ, Parikka M, Rämet M. An adult zebrafish model for preclinical tuberculosis vaccine development. Vaccine. 2013; 31(45); 5202-5209. [PubMed: 24055305].
Randhawa et al., 2011: Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, Lerumo L, Hughes J, Hussey G, Hawkridge A, Kaplan G, Hanekom WA, Hawn TR. Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. PLoS pathogens. 2011; 7(8); e1002174. [PubMed: 21852947].
Singh et al., 2011: Singh VK, Srivastava V, Singh V, Rastogi N, Roy R, Shaw AK, Dwivedi AK, Srivastava R, Srivastava BS. Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis infection in mice. Vaccine. 2011; 29(29-30); 4754-4760. [PubMed: 21565242].
Singhal et al., 2011: Singhal A, Mathys V, Kiass M, Creusy C, Delaire B, Aliouat el M, Dartois V, Kaplan G, Bifani P. BCG induces protection against Mycobacterium tuberculosis infection in the Wistar rat model. PloS one. 2011; 6(12); e28082. [PubMed: 22162757].
SWEDBERG, 1951: SWEDBERG B. Studies in experimental tuberculosis; an investigation of some problems of immunity and resistance. Acta medica Scandinavica. Supplementum. 1951; 254; 1-120. [PubMed: 14837707].
Thom et al., 2012: Thom RE, Elmore MJ, Williams A, Andrews SC, Drobniewski F, Marsh PD, Tree JA. The expression of ferritin, lactoferrin, transferrin receptor and solute carrier family 11A1 in the host response to BCG-vaccination and Mycobacterium tuberculosis challenge. Vaccine. 2012; 30(21); 3159-3168. [PubMed: 22426328].
Tsenova et al., 2006: Tsenova L, Harbacheuski R, Moreira AL, Ellison E, Dalemans W, Alderson MR, Mathema B, Reed SG, Skeiky YA, Kaplan G. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infection and immunity. 2006; 74(4); 2392-2401. [PubMed: 16552069].
Wang et al., 2009: Wang QL, Pan Q, Ma Y, Wang K, Sun P, Liu S, Zhang XL. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis. Vaccine. 2009; 27(48); 6712-6722. [PubMed: 19733584].
Fontán et al., 2008: Fontán PA, Aris V, Alvarez ME, Ghanny S, Cheng J, Soteropoulos P, Trevani A, Pine R, Smith I. Mycobacterium tuberculosis sigma factor E regulon modulates the host inflammatory response. The Journal of infectious diseases. 2008; 198(6); 877-885. [PubMed: 18657035].
Hernandez et al., 2010: Hernandez Pando R, Aguilar LD, Smith I, Manganelli R. Immunogenicity and protection induced by a Mycobacterium tuberculosis sigE mutant in a BALB/c mouse model of progressive pulmonary tuberculosis. Infection and immunity. 2010; 78(7); 3168-3176. [PubMed: 20457786].
FDA: TICE BCG: FDA TICE BCG information [http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM163039.pdf]